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Abstract 
The athlete's heart is an exercise-induced cardiac remodelling phenomenon, which is 
individual and depends on the intesity, duration and frequency of training, as well as genetic 
factors. Cardiovascular screening prior to participation in sports activities, is a systematic 
practice of medical evaluation in the athlete population. The current US recommendations for 
the screening of cardiovascular abnormalities in high school and university athletes at all levels 
of performance were initially put forther by the American Heart Association in 2007. These 
recommendations consist of 12 points, factoring personal and family history data, as well as 
physical examination. On the other hand, European recommendations suggest the importance of 
non-invasive diagnostic methods, such as the 12-lead ECG, which should be carried out in 
combination with a history and physical examination. According to the European Association 
for Cardiovascular Imaging, standard echocardiography is the first line approach to differentiate 
an athlete`s heart from pathological left ventricular hypertrophy. Updated ,,Seattle criteria’’from 
2017. include criteria for assessing abnormalities in the electrocardiogram of athletes and their 
differentiation from the adaptive electrophysiological changes, which do not require further 
evaluation. Since sudden cardiac death during sport activities remains a major concern and, as 
such, it is imperative for the physician to diagnose unrecognized pathological conditions in 
athletes. Following current expert consensus recommendations on this topic helps to prevent 
untoward events during physical activity in those who are found to be at elevated risk. 
 






The concept of athlete`s heart was first described in the literature at the end of the 
19th century, when, almost simultaneously, Henschenand Darling published their 
observations of heart enlargement in Norwegian skiers and Harvard rowers. The first 
electrocardiographic (ECG) and radiological studies dealing with the athlete`s heart 
were made in the early 1960's (1-3). 
The athlete`s heart is an exercise-induced cardiac remodelling phenomenon. This 
term was introduced for the first time in 1902, and considers a set of morpho-functional 
and electrophysiological cardiovascular changes that arise as an adaptive response of 
the heart and blood vessels to increased hemodynamic requirements during high volume 
exercise/sports training (4). Today, these changes are known to be individual and 
depend on the intensity, duration and frequency of training, as well as genetic 
phenotype (5,6). 
In the past century, left ventricular hypertrophy has been found to be the most 
common morphological change in the heart of athletes (7). The development of 
diagnostic procedures such as echocardiography enabled contemporary studies to make 
a distinction between physiological left ventricular hypertrophy in athletes and 
hypertrophic cardiomyopathy, the latter being a hereditary disease that leads to 
electrical instability in the heart or sudden cardiac death in severe cases (8). The sudden 
cardiac death of an athlete is always a tragic event that shakes both the medical 
community and the general public, these deaths are most often caused by undetected 
cardiovascular diseases (9). Among these cardiovascular diseases, hypertrophic 
cardiomyopathy is the most common, occuring in almost one third of the cases and it is 
followed by congenital anomalies of the coronary arteries, dilatative cardiomyopathy, 
congenital heart defects, and others (10,11). In addition to the changes in the left 
ventricle, the importance of right heart disorders has been established over the last 
several decades (10). 
Guidelines/propositions for diagnostics 
Cardiovascular pre-participation screening, prior to participation in sports 
activities, is a systematic practice of medical evaluation in the athlete population. The 
purpose of this evaluation is identifying or raising suspicion of already existing 
abnormalities that precipitate progression of disease or sudden death (11). In other 
words, this screening determines medical clearance for participation in competitive 
sports. Although the screening process should include an assessment of all physiologic 
systems, there is a cardiovascular focus, given the most likely to cause of an untorward 
event in athletes is sudden cardiac death. Raising the suspicion of cardiac abnormalities 
is only the initial step in a potential diagnosis, warranting additional diagnostic tests to 




At the 36th Bethesda Conference guide was developed with an algorythm that 
defines recommendations for the further actions in those who have a definite diagnosis 
of cardiac disease (12). There are three possibilities following a medical evaluation; 1) 
continuing active participation; 2) exclusion from sports; or 3) considering prophylactic 
or therapeutic interventions in those who have high-risk, genetically-conditioned, heart 
conditions (e.g., cardioverter defibrillator (ICD) implantation).These recommendations 
relate primarily to the mass screenings conducted for athletes at high schools and 
universities, of all races and sexes, although they can be applied to juniors (athletes 
under 12 years old), seniors (athletes older than 30), as well as in the clinical assessment 
of a small groups of athletes or individuals. In these small groups, pre-participation 
screening often involves non-invasive diagnostic methods, in addition to anamnesis and 
physical examination (12). 
In most countries screening for cardiovascular disease is only performed in elite 
athletes (at international and Olympic competitions). The exceptions are the United 
States, Italy and Israel, which use comprehensive screenings for athletes across a wider 
skill spectrum (i.e., not only the elite athletes) (12). 
The current US recommendations for the screening of cardiovascular 
abnormalities in high school and university athletes at all levels of performance were 
initially put forther by the American Heart Association (AHA) in 2007 (13). These 
recommendations consist of 12 points, factoring personal and family history data as 
well as physical examination. Questions from personal history capture the presence of 
chest pain or discomfort, increased blood pressure, previously observed heart murmur, 
or unexplained syncope or dyspnea related to physical activity. Significant family 
history data include the incidence of premature death due to heart disease in one or 
more close relatives under the age of 50, a disability due to heart disease in the close 
relatives before the age of 50, the existence of hypertrophic or dilatative 
cardiomyopathy, a prolonged QT interval syndrome or other ion channelopathies in 
family members. During the physical examination, it is important to record heart 
murmurs, femoral pulse (to exclude coarctation of the aorta), Marfan syndrome signs 
(connective tissue disease causing sudden death), and elevated blood pressure measured 
in the resting sitting position (13). A positive response to any of these 12 questions (or 
more) arouses suspicion of cardiovascular abnormalities and should be an indication for 
further diagnosis (13). 
The AHA's official position is that non-invasive diagnostic methods, such as ECG 
and echocardiography, should not be conducted as a mass, universal screening. There 
are several reasons for this: the size of the population of athletes who would be subject 
to mass screening is very high, while the prevalence of cardiovascular conditions that 
leads to fatalities in sports is still very small. Furthermore, the availability of resources 




professionals which are able to adequately interpret the results. Consequently, the 
number of false positive results would be notable, which would lead to unnecessary 
anxiety among athletes and unjustified exclusion from sports. However, this is not 
diminishing the value of ECG, as it can detect 90% of hypertrophic cardiomyopathy 
cases, which is the most common cardiovascular cause of sudden death of athletes (13). 
On the other hand, European recommendations, which take into account 25-year-
old Italian research in this area, suggest the importance of non-invasive diagnostic 
methods, such as the 12-lead ECG, which should be carried out in combination with a 
history and physical examination (14,15). They report a decline in athletes' mortality 
due to cardiovascular deaths by as much as 90% annually in the Veneto region of 
northern Italy due to this approach. New recommendations of the European Society of 
Cardiology (ESC) are based on the diagnostic evaluation of only those athletes who 
develop ECG changes unrelated to sports which could be an indicator of a deadly heart 
disease (16). On the other hand, there are some ECG changes common for highly 
trained athletes that should be considered as a physiologic phenotype, not warranting 
additional diagnostics, and allowing for continued participation in sports. Moreover, 
athletes falling into this physiologic phenotype category are likely engaged in sports an 
absence of symptoms or positive family history for heart disease or sudden cardiac 
death. The recommended approach in performing screening involves an evaluation of 
family and personal history, physical examination with mandatory blood pressure 
measurement and the 12-lead ECG. In the case of a negative family history, and the 
absence of symptoms and pathological findings during a physical examination, athletes 
are allowed to participate in sports without additional evaluation. The athletes who have 
been diagnosed with ECG changes from group I, which develop as an adaptive response 
to training (e.g., sinus bradycardia, first-degree atrio-ventricular block, early 
repolarization, uncomplicated block of the right branch, isolated QRS voltage criteria 
for the right chamber hypertrophy), are also allowed to continue sports activity (16). 
In the case of a the positive family history, the presence of symptoms or 
pathological findings during physical examination, as well as ECG changes in group II 
(e.g., T wave inversion, ST segment depression, pathological Q wave, enlargement of 
the left atrium, deviation of the axis to the left / left anterior fascicular block, deviation 
of the axis to the right / left posterior fascicular block, right ventricular hypertrophy, 
preexcitation of the chamber, left or right bundle branch block, prolonged or shortened 
QT interval, Brugada-like early repolarization), further diagnostics tests, such as 
echocardiography, stress test, 24-hour holter monitoring, nuclear magnetic resonance 
imaging of the heart, electrophysiological investigations, angiography, and 





According to the European Association for Cardiovascular Imaging (EACVI), 
standard echocardiography is the first line approach to differentiate an athlete`s heart 
from pathological left ventricular hypertrophy. In professional athletes, end-diastolic 
diameter of the left ventricle greater (on average about 60 mm) compared to 
hypertrophic cardiomyopathy (about 45 mm) (18,19). In professional athletes, left 
ventricular hypertrophy involves all segments of the myocardium equally and the 
thickness of the interventricular septum should not exceed 12 mm (20). In contrast, in 
hypertrophic cardiomyopathy, the septum is usually >15 mm (21). Sharma et al. 
Proposed the diagnostic criteria for hypertrophic cardiomyopathy be established at a 
heart septum thickness of 12 mm or more (22). After three months of physical 
deconditioning, a reduction in wall thickness of the left ventricle is observed in athletes, 
but not in hypertrophic cardiomyopathy (23). The EACVI experts have consensus that 
left ventricular hypertrophy in athletes is characterized by a normal ejection fraction, 
either normal or increased systolic volume, while the maximal left ventricular systolic 
wall motion velocity (more precisely its anulus) is greater than 9 cm/s. On the other 
hand, in hypertrophic cardiomyopathy, this velocity is less than 9 cm/s, and the ejection 
fraction may be normal or even increased at the onset of the disease, but at an advanced 
stage will decrease. Diastolic cardiac function is usually supernormal in athletes, which 
is primarily reflected by the ratio of the early and late diastolic left ventricular filling 
velocities (E/A), which is in their case greater than 2, whereas in hypertrophic 
cardiomyopathy less than 1 (24). Using echocardiography, Pelicia et al also proposed 
the upper limit of the antero-posterior left atrial diameter at athletes be set at 45 mm for 
women and 50 mm for men; values greater than these indicate pathological conditions 
(21). 
Standard echocardiography is also a preferred method for differentiating right 
ventricular remodeling in the athlete`s heart and pathological enlargement of the right 
ventricle (25,26). 
In addition, it is expected that echocardiography may also diagnose other 
abnormalities of the cardiovascular system that may be the cause of sudden cardiac 
death in athletes, such as aortic stenosis, mitral valve prolapse, aortic root dilatation 
within Marfan`s syndrome, dilatative cardiomyopathy, or arrhythmogenic 
cardiomyopathy of the right ventricle (10). 
Apart from resting echocardiography, it is posssible to screen athletes by using 
echocardiography during physical activity (i.e., stress echocardiography). This method 
is of moderate sensitivity and specificity for determination of the existence of coronary 
artery disease. For instance, if there is reduced resting ejection fraction in an athlete, 




effort. This can be quatified by stress echocardiography. If contractility during physical 
activity is maintained, the probability of coronary disease is low (27).  
Electrocardiography 
In 2012, the American Medical Association of Sports Medicine (AMSSM), 
sponsored by the FIFA Center for Medical Assessments and Research, held a Summit 
on the Interpretation of Athletes' Electrocardiograms in Seattle, Washington. At this 
meeting, the criteria for assessing abnormalities in the electrocardiogram of athletes and 
their differentiation from the expected and adaptive electrophysiological changes, which 
do not require further evaluation, were defined (28). These criteria are called the 'Seattle 
Criteria'. Updated criteria from 2017 (29) include the following: 
1. T wave inversion (≥1 mm in depth in two or more contiguous leads; excludes 
leads aVR, III and V1) 
2. ST segment depression ≥0.5 mm in depth in two or more contiguous leads 
3. Pathological Q waves Q/R ratio ≥0.25 or ≥40 ms in duration in two or more 
leads (excluding III and aVR)  
4. Complete left bundle branch block QRS ≥120 ms, predominantly negative 
QRS complex in lead V1 (QS or rS) and upright notched or slurred R wave in 
leads I and V6  
5. Profound non-specific intraventricular conduction delay (any QRS duration 
≥140 ms) 
6. Epsilon wave - a distinct low amplitude signal (small positive deflection or 
notch) between the end of the QRS complex and onset of the T wave in leads 
V1-V3 
7. Ventricular pre-excitation PR interval <120 ms with a delta wave (slurred 
upstroke in the QRS complex) and wide QRS (≥120 ms)  
8. Prolonged QT interval: QTc ≥470 ms (male), QTc ≥480 ms (female), 
QTc ≥500 ms (marked QT prolongation)  
9. Brugada type 1 pattern - coved pattern: initial ST elevation ≥2 mm (high take-
off) with downsloping ST segment elevation followed by a negative 
symmetric T wave in ≥1 leads in V1-V3  
10. Profound sinus bradycardia (<30 beats per minute or sinus pauses ≥3 s) 
11. Profound 1° atrioventricular block ≥400 ms  
12. Mobitz type II 2°  atrioventricular block (intermittently non-conducted P 




13. 3° atrioventricular block (complete heart block)  
14. Atrial tachyarrhythmias, (supraventricular tachycardia, atrial fibrillation, atrial 
flutter) 
15. Premature ventricular contractions (≥2 premature ventricular contractions per 
10 s tracing)  
16. Ventricular arrhythmias (couplets, triplets and non-sustained ventricular 
tachycardia) 
Other diaganotics methods 
In the late 1980s and the 90s, the importance of contrast nuclear magnetic 
resonance (NMR) of the heart was recognized as useful diagnostic methods for 
assessing regional and global myocardial contractility. Contemporary work by Rickers 
C et al.and Moon JC et al. reveals the high sensitivity and specificity of this method in 
differentiating the athlete`sheart from hypertrophic cardiomyopathy and idiopathic 
dilatative cardiomyopathy (30,31). Moreover, Scharf M. et al. (32) demonstrated that 
cardiac NMR imaging is a good alternative to echocardiography in the assessment of 
left atrial volume, as echocardiography has a tendency for its underestimation. 
The EACVI supports consideration of cardiac NMR, coronary computed 
tomography angiography (CCTA), and perfusion techniques such as single-photon 
emission computed tomography (SPECT) and positron emission tomography (PET) in 
symptomatic patients with suspected anomalies or coronary artery disease. 
Conclusion 
Since sudden cardiac death during sport activities remains a major concern and, as 
such, it is imperative for the physician to diagnose unrecognized pathological conditions 
in athletes. In athletes found to have cardiac conditions but continue to engage in sport 
activities, the role of physicians is significant in prescribing exercise intensity. Physical 
activity has vast beneficial effects, but, as it entails exertional stress, detailed health 
assessments become important before engaging in high intensity training. Following 
current expert consensus recommendations on this topic helps to prevent untoward 
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Kratak sadržaj 
Atletsko srce je fenomen remodelovanja srčanog mišića, koje je nastalo usled fizičke 
aktivnosti, a čiji stepen zavisi od intenziteta, trajanja, učestalosti treniranja, individualnih 
osobina i genetskih faktora. Aktuelne američke preporuke za skrining kardiovaskularnih 
abnormalnosti među sportistima srednjoškolcima i studentima svih nivoa utreniranosti, 
inicijalno su bile postavljene od strane Američkog udruženja kardiologa 2007. godine. Ove 
preporuke čini 12 tačaka i podrazumevaju podatke iz lične i porodične istorije bolesti, kao i 
fizičkog pregleda. S druge strane, evropske preporuke sugerišu na značaj neinvazivnih 
dijagnostičkih metoda, kao što je 12-kanalni EKG, čiji rezultati bi trebali biti razmatrani 
udruženo sa istorijom bolesti i fizičkim pregledom. Prema Evropskom udruženju za 
kardiovakularni imidžing, standardna ehokardiografija je prva dijagnostička metoda 
diferencijacije sportskog srca od patološke hipertrofije leve komore. Godine 2012, Američko 
udruženje za sportsku medicine je definisalo kriterijume, koji su osveženi 2017. godine, za 
utvrđivanje abnormalnosti u elektrokardiogramu sportista i njihovu diferencijaciju od adaptivnih 
elektrofizoloških promena, koje ne zahtevaju dalju evaluaciju. S obziromna to da iznenadna 
srčana smrt u sportu zahteva veliku pažnju, neophodno je da lekari budu edukovani da 
dijagnostikuju neprepoznata patološka stanja kod sportista. Praćenje aktuelnih preporuka koje  
se bave ovim problemom doprinosi prevenciji neželjenih događaja u sportu i kod osoba koje su 
iz drugih razloga izložene velikim fizičkim naporima. 
 
Ključne reči: atletsko srce, skrining, hipetrofija leve komore 
 
